Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Apr 19:4:10.
doi: 10.1038/s41392-019-0045-x. eCollection 2019.

Normalization cancer immunotherapy: blocking Siglec-15!

Guangchao Cao  1 , Zhiqiang Xiao  1 , Zhinan Yin  1   2
Affiliations
Comment

Normalization cancer immunotherapy: blocking Siglec-15!

Guangchao Cao et al. Signal Transduct Target Ther. .
No abstract available

Keywords: Immunotherapy; Tumour immunology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Fig. 1
Fig. 1
Siglec-15 is a candidate target for normalization cancer immunotherapy. Siglec-15 is minimally expressed on normal tissues at steady-state. However, the expression of Siglec-15 is redundant in a broad spectrum of human cancers and tumor associated myeloid cells. Interestingly, Siglec-15 is mutually exclusive to B7-H1 in human non-small cell lung cancer, which may partially due to its induction by M-GSF and suppression by IFN-γ. Siglec-15 engages with a putative responder protein expressed on effector cells such as CD8 T cells, which induces subsequent suppression of anti-tumor immune responses. Blocking Siglec-15 amplifies anti-tumor immunity in the tumor microenvironment and inhibits tumor growth
See this image and copyright information in PMC

Comment on

References

    1. Wang J, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med. 2019;25:656–666. doi: 10.1038/s41591-019-0374-x. - DOI - PMC - PubMed
    1. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–723. doi: 10.1016/j.cell.2017.01.017. - DOI - PMC - PubMed
    1. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313–326. doi: 10.1016/j.cell.2018.09.035. - DOI - PMC - PubMed
    1. Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J. Exp. Med. 2016;213:2835–2840. doi: 10.1084/jem.20161462. - DOI - PMC - PubMed
    1. Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology. 2013;23:178–187. doi: 10.1093/glycob/cws139. - DOI - PubMed

MeSH terms

Substances